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ABSTRACT 
Obesity is a complex interplay between environmental and genetic factors, is also associated with 
significant morbidity and mortality. The primary objective of the present study was to evaluate the 
efficacy and safety of Calebin A (standardized extract of Curcuma caesia) in the management of weight in 
obese or overweight individuals. A randomized, mono-centric, double-blind, placebo-controlled, clinical 
study was conducted by administering Calebin A (standardized extract of Curcuma caesia) capsules 
(25 mg, one capsule twice a day) and indistinguishable placebo capsules as daily supplements to 40 
overweight and obese subjects for 90 days. The study participants were divided in 1:1 ratio to receive 
either Calebin A (standardized extract of Curcuma caesia) (n = 20) or placebo (n = 20).  
Efficacy was assessed by measuring body weight, body mass index, leptin, adiponectin levels, total 
cholesterol, HDL cholesterol, LDL cholesterol, triglycerides and Hs-CRP. Safety was assessed by 
evaluating safety parameters (vital signs and laboratory investigations) and monitoring adverse events. 
After 90 days, significant reduction in body weight (P< 0.0001) and body mass index (P < 0.0001) were 
observed in the Calebin A (standardized extract of Curcuma caesia) group compared with placebo. 
Additionally, significant change in serum biomarkers was observed between Calebin A (standardized 
extract of Curcuma caesia) and placebo groups from baseline to final visits. Adverse events were mild and 
were unrelated to the investigational products. Supplementation with Calebin A (standardized extract of 
Curcuma caesia) resulted in significant decrease in weight loss than placebo over 90 days. It was safe and 
well tolerated by all subjects. 
KEYWORDS: Curcuma caesia, Leptin, Adiponectin, Body weight, Body mass index. 
INTRODUCTION
 Obesity arises from an imbalance in energy 
consumption over energy expenditure.1 At the cellular 
level, this imbalance results in an increase in the size and 
number of mature adipocytes.2–4 
 In 2008, the world health organization estimated 
that about 1.5 billion adults (aged 20 and above) were 
overweight with nearly 500 million of these individuals 
classified as obese.5 
 The study - titled 'Global, regional, and national 
prevalence of overweight and obesity in children and 
adults during 1980-2013: A systematic analysis for the 
global burden of disease study 2013' - used data collected 
by international bodies and organisations in various 
countries like India over three decades. The US topped the 
list with 13 per cent of the obese people worldwide in 
2013, while China and India together accounted for 15 per 
cent of the world's obese population, with 46 million and 
30 million obese people, respectively. According to the 
study, number of overweight and obese people globally 
increased from 857 million in 1980 to 2.1 billion in 2013. 
This is one-third of the world's population.  
 Overweight in adults is categorised as those with 
Body Mass Index of 25 kg/m2 to 30 kg/m2 and obesity as 
those with Body Mass Index of more than 30 kg/m2. As per 
the study, in 2010, overweight and obesity were estimated 
to cause 3 to 4 million deaths, 3.9 per cent of years of life 
lost and 3.8 per cent of disability adjusted life-years 
worldwide.  
 With lifestyle disorders forcing more and more 
people to reel under excess body weight, even relatively 
younger people are developing joint disorders and knee 
pain. Excessive weight is associated with a series of health 
problems, including blood pressure, diabetes and 
cardiovascular ailments. Yet another problem is that 
obesity puts people at an increased risk of developing 
osteoarthritis. Experts say the prevalence of obesity is 
greater in urban areas, and more women are affected than 
men.6 
 Current treatments for obesity include 
pharmacotherapy, bariatric surgery and lifestyle 
modification.7 Pharmacotherapy involves the use of anti-
obesity drugs such as phentermine and orlistat.8, 9 
 The preferred treatment modality for weight loss 
is dieting and physical exercise. Due to busy schedules and 
sedentary lifestyle follow-up the first two methods never 
seems to be practiced in a regular manner. On the other 
hand, weight loss surgery runs out of the option 
considering the cost involved. There is a gradual shift 
towards an increased use of drugs. Drugs are 
pharmacological agents that reduce or control weight. 
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These drugs alter one of the fundamental processes of the 
human body. Due to potential side effects, it is 
recommended that anti-obesity drugs only be prescribed 
for obesity where it is hoped that the benefits of the 
treatment outweigh its risk.10 
 The use of allopathic and pharmacological drugs 
has become a popular means to overcome excess weight 
gain.11 While these drugs generally are effective, severe 
adverse toxicities may limit their overall usefulness.12, 13 A 
nutritional based intervention is being hailed as an 
inexpensive alternative to aid weight loss, and weight 
management.14 Natural plant based phytoextracts with 
enriched phytonutrients in the form of supplements are 
being extensively utilized due to their effectiveness in 
managing many chronic disorders. They are cost-effective, 
and exert less to no toxic side-effects in comparison with 
many chemically synthesized drugs.15 Accordingly, recent 
preliminary reports suggested that herbs with a long 
history of use and other natural substances less likely to 
produce severe toxicity might be effective in reducing 
appetite and promoting significant weight loss are 
encouraging.16 
 Curcuma caesia Roxb (black turmeric) is a 
perennial herb with bluish black rhizomes and it is famous 
for its medicinal properties. 
 Calebin A, being a ferulate ester lacks the 
characteristic feature of curcuminoid i.e., 1, 3-diketonic 
structure.17 
 A study conducted to investigate the chemo 
preventive effects of dietary Curcuma caesia (Calebin A) on 
differentiation of 3T3-L1 adipocytes and high-fat diet 
(HFD) induced obesity and hepatic steatosis. Potential 
mechanisms contributing to these effects were also 
elucidated. 
  
Calebin A effectively and dose dependently suppressed 
accumulation of lipid droplets in adipocytes through the 
suppression of adipogenic specific factor peroxisome 
proliferator-activated receptor (PPAR) γ and fatty acid 
synthesis and activated acetyl-CoA carboxylase. Dietary 
Calebin A effectively decreased weight gain and relative 
perigonadal, retroperitoneal and mesenteric fat weight in 
HFD-fed mice.18 
 Based on the above study, Sami Labs Limited 
conducted a repeated dose (90 day) study to assess the 
oral toxicity, reproductive/developmental toxicity and 
mutagenic potential of Curcuma caesia (Calebin A).  
 Curcuma caesia (Calebin A) was orally 
administered to groups of 10 male and/or 10female 
Wistar rats each, assigned to three dose levels (20, 50 and 
100 mg/kg/body weight)once daily for 90 consecutive 
days. None of the animals in any of the treatment/control 
groups exhibited any abnormal clinical signs/behavioural 
changes, reproductive as well as developmental 
parameters, or gross and microscopic changes in both 
male and female rats.19 
 We hypothesized that Curcuma caesia (Calebin A) 
would help in weight management of obese or overweight 
individuals.  
MATERIALS &METHODS 
Study Product Description 
 Calebin A (standardized extract of Curcuma 
caesia) was encapsulated in size zero hard Gelatin capsules 
with excipients. Placebo capsules with equivalent weight 
of micro-crystalline cellulose. No differences in colour, 
taste, texture or packaging were detectable between the 
two products. Capsules were sealed in identically-
appearing, high-density polyethylene bottles with 
desiccant. 
Table 1: Composition detail of Curcuma caesia capsule 
# Ingredients Label Claim Overages mg per capsule 
1 Calebin A (standardized extract of Curcuma caesia) 25 mg 5% 26.25 
2 Micro-crystalline cellulose 368.75 
3 Magnesium stearate 5.0 
‘00’ Golden Yellow/ Golden Yellow HG capsules 
Ethics Approval 
 The study protocol and related documents were 
reviewed by Institutional Ethics Committee of Life Care 
Hospital, Bangalore, prior to study initiation. The aforesaid 
Ethics Committee was registered under CDSCO as per the 
Gazette Notification Number F.28-10/45-H(1), dated 21 
DEC 1945 and last amended vide notification number 
G.S.R. 76(E) dated 08 FEB 2012. 
Informed Consent 
 Written and oral information about the study in a 
language understandable by the subject was provided to 
all subjects. Each subject was informed by the investigator, 
prior to the screening evaluation, of the purpose of this 
clinical trial, including possible risks and benefits and 
documented the informed consent process in the subject’s 
chart. Prior to entry into the study or initiation of any 
study-related procedures, the subject read, signed and 
dated the Institutional Ethics Committee approved 
informed consent form. Sufficient time was provided for 
each subject to decide whether to participate in the study 
and all the questions and clarifications regarding the study 
were clarified by the investigator. The person executing 
the consent also signed and dated the final consent form 
page.  
Participants 
 A total of forty subjects were enrolled in the study. 
Eligibility requirements included male and female 
patient’s age between 20 and 65 years and body mass 
index (BMI) between 25 to 40 Kg/m2. Subjects willing to 
come for regular follow-up visits and able to give written 
informed consent were recruited. 
Muhammed Majeed et al. Efficacy and Tolerability of A Novel Formulation for Weight Management in Obese Subjects 
 Available online at: http://ijapr.in  12 
 Subjects were excluded if they were not otherwise 
healthy, were pregnant or nursing and had in previous six 
months taken over the counter weight loss agents, 
centrally acting appetite suppressants or prior surgical 
therapy for obesity. Patients with pathophysiologic/ 
genetic syndromes associated with obesity, evidence of 
malignancy, poorly controlled Diabetes mellitus or 
hypertension or clinical evidence of heart failure were 
excluded. Alcoholics and/or drug abusers as well as 
patients with history of HIV and other viral infections or 
history of hypersensitivity to any herbal extract or dietary 
supplement. Patients were not included if they have 
concurrent serious hepatic disorder (AST/ALT, total 
bilirubin, ALP > 2 times upper normal limit) or renal 
disorders (serum creatinine> 1.2 mg/dL) or severe 
pulmonary dysfunction or patients on prolonged (> 6 
weeks) medication with corticosteroids, antidepressants, 
anticholinergics, etc. 
Trial Design 
 The clinical trial was a randomized, double-blind, 
placebo-controlled, clinical study to evaluate the efficacy 
and safety of Calebin A (standardized extract of Curcuma 
caesia).This trial study was performed at Life Care 
Hospital, Bangalore. At baseline evaluation, subjects were 
provided active or placebo capsules, compliance cards and 
dates for follow-up evaluations. 
 All subjects filled out a questionnaire providing 
details regarding medical history and the diet at baseline 
as well as all follow-up evaluations at Day 30, Day 60 and 
Day 90. At baseline and subsequent follow-up visits, 
subjects were assessed for body weight, body mass index 
and waist and hip circumference, serum biomarkers 
(leptin, adiponectin, ESR and Hs-CRP), lipid profile and 
clinical photographs. Safety was assessed by determining 
changes in vitals, blood chemistries, liver enzymes, 
adverse events. 
Supplementation 
 All participants in the experimental group 
received Calebin A (standardized extract of Curcuma 
caesia) supplementation over a 90 day period. The 
participants in the placebo group received capsules of 
similar size and colour. They were given identical 
instructions on dosage of study supplement to be followed. 
Active and placebo were supplied in opaque white plastic 
bottles containing a known number of capsules. Subjects 
were directed to take one capsule at least 30 minutes after 
meal, twice a day (2 capsules per day) and to return 
unused pills, which were counted to determine adherence. 
The administration of treatment and placebo was blinded 
for both the participants and the investigator. At the end of 
the study, a representative of Sami Labs Limited revealed 
the supplement code to the researchers. There were no 
side effects reported by the participants as a result of the 
supplementation. 
Randomisation & Allocation Concealment 
 The randomisation sequence was prepared by an 
independent statistician, independent of the sponsoring 
organization and not involved in conduct or reporting of 
the study. Alphabetical code was generated for both the 
active and placebo to improve the blindness of the study 
and concealment of allocations. Computer generated 
random allocation software (version 2.0) was used for the 
allocation of concealment. Block randomization (only one 
block) was followed wherein the subjects were 
randomized to receive either active or placebo. The 
randomization codes were kept strictly confidential and 
were accessible only to authorized persons on an 
emergency basis as per the Sponsor standard operating 
procedures until the time of unblinding. 
Blinding 
 The study was double blinded wherein neither the 
Investigator nor the trial participants knew whether they 
would receive Calebin A (standardized extract of Curcuma 
caesia) or placebo. The investigational products were 
provided in pre labelled containers to avoid bias. 
Statistical Analysis 
 Statistical Analysis Software (SAS) of version 9.2 
software was used for data analysis. Paired ‘t’ test, Analysis 
of Covariance (ANCOVA) and Wilcoxon signed rank sum 
test were used for appropriate data set variables to reach 
the best possible statistical conclusion between Curcuma 
caesia (Calebin A) and Placebo groups. The baseline 
descriptors were summarized as mean and standard 
deviations for continuous variables and as frequencies and 
percentages for categorical variables. p-values less than 
0.05 were considered to be statistically significant for 
between-group comparisons. All comparisons reported are 
between the placebo and the Curcuma caesia (Calebin A) 
groups at each specified time point. 
Results 
Demographic Characteristics: Demographic 
characteristics of the study subjects are summarized in 
Table 2. 
Reduction in body weight and BMI 
 The present study evaluated the efficacy of 
Curcuma caesia (Calebin A) on weight loss, lipid profiles, 
serum adiponectin level in comparison with placebo 
group. Curcuma caesia (Calebin A) supplementation for 90 
days resulted in statistically significant reduction in body 
weight and BMI (p< 0.0001) (Table 2).  
Changes in Waist and Hip Circumferences 
 The reduction in waist circumferences, after 
supplementation with placebo or Curcuma caesia (Calebin 
A), is summarized in Table 2. 
 Supplementation with the Curcuma caesia 
(Calebin A) resulted in net decrease (p<0.0001) in waist 
circumferences at the end of the study. It was also found 
that the net impact of the Curcuma caesia (Calebin A) on 
waist circumference was statistically significant compared 
with placebo. 
Improvement in Serum Adiponectin 
 Curcuma caesia (Calebin A) supplementation 
resulted in (p <0.01) increase in serum adiponectin 
concentration compared to the placebo group at the end of 
the study (Figure 2).This observation suggests the reduced 
fat store in Curcuma caesia (Calebin A) supplemented 
subjects. Interestingly, it is also suggestive that Curcuma 
caesia (Calebin A) might be a potential candidate for 
improving cardiovascular health in obese humans. 
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Modulation of Serum Markers and Lipid Profile 
 Figures 3 and 4 illustrate that Curcuma caesia 
(Calebin A) supplementation for 90 days resulted in a 
significant decrease of leptin levels and Hs-CRP (p< 0.01) 
compared with placebo. 
 It was noted that Curcuma caesia (Calebin A) 
supplementation significantly decreased total cholesterol, 
LDL cholesterol and triglyceride levels and increased HDL 
cholesterol levels (p< 0.0001) (Table 4).  
Adverse Events 
 No major adverse events were reported during 
this study. Minor adverse events such as gastrointestinal 
irritation, leg pain were noted at various evaluation time 
points. However, these events were not likely to be 
associated with Calebin A (standardized extract of 
Curcuma caesia) supplementation. 
Safety Evaluations 
 Vital signs such as Blood Pressure, Respiratory 
Rate, Pulse Rate and any abnormal lab parameters were 
considered for safety evaluations. No clinically significant 
changes were recorded for descriptive physical 
examination in both the groups (Calebin A (standardized 
extract of Curcuma caesia) and placebo). Further, no 
clinically significant abnormal lab values were identified 
and no statistically significant changes in the vitals were 
observed from the baseline to final visits. There were no 
serious adverse events noticed in this study. 
Dropouts 
 Five subjects (two from the Calebin A 
(standardized extract of Curcuma caesia) group and three 
from the placebo group) were dropped from the study and 
were lost to follow-up (Figure 1). The results attributed to 
the dropouts were excluded from all statistical analysis. 
DISCUSSION 
 A total of 41 subjects were screened and 40 were 
enrolled into the study and randomized into Curcuma 
caesia (Calebin A) and placebo groups in 1:1 ratio for a 
period of 90 days, as one capsule twice a day, at least 30 
minutes after meals reported significant decrease in 
weight towards end of the study in Curcuma caesia 
(Calebin A) receiving group when compared to placebo 
receiving group. The clinical efficacy parameters of 
anthropometric, lipid profile and serum biomarkers have 
suggested that the group receiving Curcuma caesia 
(Calebin A) is showing a good trend in the reduction of 
weight.  
 Lipid parameters for patients receiving Curcuma 
caesia (Calebin A) showed significant decrease in total 
cholesterol, triglycerides, LDL cholesterol and a significant 
increase in HDL cholesterol. Serum biomarkers analysis 
(adiponectin, leptin, hs-CRP, Erythrocyte Sedimentation 
Rate) showed that Curcuma caesia (Calebin A) was 
significantly effective when compared to placebo.  
 There were no major study product related 
adverse events. Minor adverse effects reported in the 
study were all unrelated to the investigational products. 
With no abnormal laboratory values, changes in the vital 
signs, and with no statistical difference (P>0.05) between 
the treatment groups, Curcuma caesia (Calebin A) as 
dietary supplement could be confirmed showing 
significant efficacy for overweight/obesity.  
 This study provides preliminary evidence on 
weight loss benefits of Curcuma caesia that are in line with 
other studies conducted elsewhere across the world.  
CONCLUSION 
 Obesity and overweight are serious health 
problems that have reached epidemic proportions. Weight 
problems can have a negative impact on quality of life and, 
in the case of obesity, can even lead to a significant 
reduction in life expectancy. Due to safety concerns and 
side effects of many prescription weight loss drugs, herbal 
remedies are becoming increasingly popular as 
alternatives to prescription medications for weight loss. 
 The present study demonstrated significant 
beneficial effects on body weight, anthropometry, lipid 
profile, biomarkers, lipid parameters, biomarkers. No 
study product related adverse events were reported. 
 In summary, the results of current clinical study 
reveal that Curcuma caesia (Calebin A) may be an effective 
and safe nutraceutical in reducing weight in overweight/ 
obese adults. Thus, we conclude that larger multi-site trials 
are needed to elucidate the potential mechanisms of action 
and role of Curcuma caesia (Calebin A) in management of 
overweight/obesity. 
Registration 
 The trial was registered on the Clinical Trial 
Registry of India with the registration number 
CTRI/2016/01/006487on 07/Jan/2016. 
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Figure 1: Flow chart of the clinical study design 
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Table 2: Demographic data and baseline characteristics of the study subjects 
Values are expressed as mean (standard deviation) 
 
Characteristics 
Placebo 
(n=17) 
Curcuma Caesia (Calebin A) 
(n=18) 
Number of males 05 05 
Number of females 12 13 
Age (years) 36.94 (8.33) 35.11 (8.83) 
Weight (kg’s) 76.9 (11.08) 90.13 (14.75) 
Height (meters) 1.56 (0.07) 1.60 (0.1) 
Body Mass Index (kg/m2) 31.30 (3.31) 34.93 (4.53) 
Screened (n = 41) 
Inclusion and 
Exclusion Criteria 
Excluded (n = 01) 
02)cluded (n = 02) 
 Enrolled = 40 
Randomized (n=40) 
 
Placebo Group (n=20) Calebin-A  Group (n =20)n=20) 
Received allocated 
intervention (n=20) 
 
 Received allocated 
Intervention (n=20) 
Allocation 
 
Discontinued intervention 
(n=03) 
 
Discontinued intervention 
(n=02) 
 
Excluded from analysis 
 (n=03) 
 
Excluded from analysis 
 (n=02) 
 
 
Follow-up 
 
Analysis 
 
Completed 
 (n= 17) 
Completed 
 (n= 18) 
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Table 3: Changes in Physical Parameters from baseline to Day 90 in the Placebo and in Curcuma caesia (Calebin A) 
supplemented group 
Parameter Study Visits Placebo (n = 17) Curcuma caesia (Calebin A) (n = 18) p Value 
Body Weight 
(kg) 
Screening 
76.9  
(11.08) 
90.13  
(14.75) 
≤ 0.0001 
Day 90 
79.11 
(11.55) 
81.94 
(15.21) 
Body Mass Index 
(kg/m2) 
Screening 
31.30  
(3.31) 
34.93  
(4.53) 
≤ 0.0001 
Day 90 
32.37 
(3.87) 
31.82 
(5.05) 
Waist 
Circumference 
(cms) 
Screening 
102.64 
(10.62) 
111.94 
(11.12) 
≤ 0.0232 
Day 90 
102.58 
(9.79) 
107.20 
(11.77) 
Values represent mean (standard deviation) 
Table 4: Changes in serum fat metabolic markers from baseline to Day 90 in the Placebo and in Curcuma Caesia 
(Calebin A) supplemented group 
Parameter Study Visits Placebo (n = 17) Curcuma caesia (Calebin A) (n = 18) p Value  
HDL Cholesterol 
Screening 
36.45 
(5.09) 
38.65 
(8.71) 
≤ 0.0001 
Day 90 
37.7 
(4.81) 
53.4 
(4.91) 
LDL Cholesterol 
Screening 
136.4 
(25.20) 
130.71 
(26.18) 
≤0.0483 
Day 90 
129.5 
(26.56) 
110.2 
(27.00) 
Total Cholesterol 
Screening 
195.35 
(29.89) 
194.78 
(34.43) 
≤ 0.0470 
Day 90 
190.1 
(31.41) 
178.0 
(33.75) 
Triglycerides 
Screening 
130.46 
(60.78) 
143.44 
(66.58) 
≤ 0.0055 
Day 90 
139.8 
(70.60) 
91.4 
(49.35) 
Values represent mean (standard deviation) 
    FIGURES: 
 
Figure 2: Serum adiponectin concentration (mean ± SD) of subjects supplemented with Calebin A and placebo were 
compared at screening and after 90 days. At the end of the study, Calebin A confers significant (p ≤ 0.01) increase in 
adiponectin level in comparison with placebo. 
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Figure 3: Hs-CRP concentration (mean ± SD) of subjects supplemented with Calebin A and placebo were compared at 
screening and after 90 days. At the end of the study, Calebin A confers significant (p ≤ 0.01) decrease in Hs CRP level in 
comparison with placebo. 
 
Figure 4: Serum leptin concentration (mean ± SD) of subjects supplemented with Calebin A and placebo at screening and 
after 90 days. At the end of the study, Calebin A confers significant (p≤0.01) decrease in leptin level in comparison with 
placebo. 
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